Wong, Yu Jun
Tran, Sally
Huang, Chung-Feng
Hsu, Yao-Chun
Preda, Carmen
Toyoda, Hidenori
Liu, Joanne
Jun, Dae Won
Landis, Charles
Huang, Daniel Q.
Gila, Andrei
Negoita, Livia
Yasuda, Satoshi
Tseng, Cheng-Hao
Tsai, Pei-Chien
Uojima, Haruki
Nozaki, Akito
Chuma, Makoto
Atsukawa, Masanori
Ishigami, Masatoshi
Itokawa, Norio
Iio, Etsuko
Lam, Carla Pui-Mei
Watanabe, Tsunamasa
Asai, Akira
Yokohama, Keisuke
Abe, Hiroshi
Enomoto, Masaru
Kawada, Norifumi
Tamori, Akihiro
Lee, Dong Hyun
Jun, Mi Jung
Do, Son
Vo, Dang K. H.
Liu, Li
Li, Junyi
Ji, Fanpu
Wang, Wenjun
Li, Yu
Wang, Xiaozhong
Guo, Fen
Xu, Qiang
Jing, Liang
Ye, Qing
Pan, Hongying
Zhang, JiaJie
Wen, Xie
Wang, Qi
Ren, Hong
Cai, Dachuan
Shang, Jia
Liu, Junping
Lu, Chengzheng
Zang, Wenqian
Li, Jia
Niu, Junqi
Zhang, Mingyuan
Wu, Chao
Huang, Rui
Maeda, Mayumi
Nakanishi, Akiko
Yeh, Ming-Lun
Chuang, Wan-Long
Huang, Jee-Fu
Dai, ChiaYen
Ishikawa, Toru
Takaguchi, Koichi
Senoh, Tomonori
Trinh, Huy N.
Takahashi, Hirokazu
Eguchi, Yuichiro
Quek, Sabrina Xin Zi
Haga, Hiroaki
Ogawa, Eiichi
Wong, Grace
Buti, Maria
Fukunishi, Shinya
Ueno, Yoshiyuki
Yuen, Man-Fung
Tanaka, Yasuhito
Lim, Seng Gee
Cheung, Ramsey
Yu, Ming-Lung
Nguyen, Mindie H. http://orcid.org/0000-0002-6275-4989
Article History
Received: 22 November 2022
Accepted: 4 May 2023
First Online: 5 June 2023
Declarations
:
: WYJ: Speaker: Gilead and AbbVie; MHN: research support: Pfizer, Enanta, Gilead, Exact Sciences, Vir Biotech, Helio Health, National Cancer Institute, Glycotest, B.K. Kee Foundation; Consulting and/or Advisory Board: Intercept, Exact Science, Gilead, GSK, Eli Lilly, Laboratory of Advanced Medicine, Janssen; AN: Speaker fee and research grant: Gilead and AbbVie; LSG: Advisory Board: Gilead Sciences, Roche, GSK, Janssen, Grifols, Assembly, Arbutus, Abbott, Sysmex; Speakers Bureau: Gilead Sciences, Abbott, Janssen; Educational/research funding: Abbott, Merck Sharpe and Dohme, Gilead Sciences, Sysmex GW: Speakers’ fees: Abbott, Abbvie, Ascletis, Bristol-Myers Squibb, Echosens, Gilead Sciences, Janssen and Roche; Research grant: Gilead Sciences; MA: Speakers’ fees: AbbVie, Gilead; Research grant: AbbVie; CHT: Speaker: Abbvie, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, and Bayer; HT: Abbie, Astellas Pharma and Sysmex Corporation; KT: Speaker: Abbie; EO: Speakers’ fees: Abbvie, Gilead Sciences; Research grant: Gilead Sciences; WLC: Speaker: Gilead, AbbVie, BMS, PharmaEssentia; Member of Advisory Board: Gilead, AbbVie, BMS, Pharma Essentia; HT: AbbVie, Gileads, Bayer, Eisai, MSD, Janssen; MFY: Advisory board member/consultant for and/or received research funding: AbbVie, Aligos Therarpeutics, AiCuris, Antios Therapeutics, Arrowhead Pharmaceuticals, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Bluejay Therapeutics, Clear B Therapeutics, Dicerna Pharmaceuticals, Finch Therapeutics, Fujirebio Incorporation, GlaxoSmithKline, Gilead Sciences, Immunocore, Janssen, Merck Sharp and Dohme, and Hoffmann-La Roche, Vir Biotechnology; YML: Consultant: Abbvie, Abbott, BMS, Gilead, Merck and Roche diagnostics; Speaker: Abbvie, Abbott, BMS, Gilead, IPSEN, Merck and Roche; YU: Speakers’ fees: Abbvie Inc, Research grant: Gilead Sciences, Abbvie; ME: Speakers’ fee: AbbVie; FJ: Speaker fees: Gilead Sciences, MSD and Ascletis, Consulting or advisory board: Gilead Sciences and MSD; YT: Speakers’ fee: Gilead Sciences, Fujirebio Inc, AbbVie, Research grants: Janssen, Gilead, Board of Trustees of the Leland Stanford Junior University, AbbVie.
: All the procedures performed in studies involving animals were in accordance with the ethical standards of the institution at which the studies were conducted and ethical approval was obtained from Stanford University, Stanford, California, USA and each participating site.